FinscoFinsco

Aurinia Pharmaceuticals (US.AUPH)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AUPH · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion99.9%→
ROE6.1%↓
Cash Conversion94.8%↑
D/E Ratio0.12↑
Gross Margin91.6%↑
US.AUPH (Aurinia Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1


Metric           Value  YoY
---------------------------
FCF Conversion   99.9%    →
ROE               6.1%    ↓
Cash Conversion  94.8%    ↑
D/E Ratio         0.12    ↑
Gross Margin     91.6%    ↑
Key Metrics
US.AUPH (Aurinia Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
---------------------------
FCF Conversion 99.9% →
ROE 6.1% ↓
Cash Conversion 94.8% ↑
D/E Ratio 0.12 ↑
Gross Margin 91.6% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies